Cancer cells depend on glutamine to sustain their increased proliferation and manage oxidative stress, yet glutamine is often depleted at tumor sites owing to excessive cellular consumption and poor vascularization. We have previously reported that p53 protein, although a well-known tumor suppressor, can contribute to cancer cell survival and adaptation to low-glutamine conditions. However, the TP53 gene is frequently mutated in tumors, and the role of mutant p53 (mutp53) in response to metabolic stress remains unclear. Here, we demonstrate that tumor-associated mutp53 promotes cancer cell survival upon glutamine deprivation both in vitro and in vivo. Interestingly, cancer cells expressing mutp53 proteins are more resistant to glutamine deprivation than cells with wild-type p53. Depletion of endogenous mutp53 protein in human lymphoma cells leads to cell sensitivity to glutamine withdrawal, whereas expression of mutp53 in p53 null cells results in resistance to glutamine deprivation. Furthermore, we found that mutp53 proteins hyper-transactivate p53-target gene CDKN1A upon glutamine deprivation, thus triggering cell cycle arrest and promoting cell survival. Together, our results reveal an unidentified mechanism by which mutp53 confers oncogenic functions by promoting cancer cell adaptation to metabolic stress.
INTRODUCTION
Glutamine is essential for survival and proliferation of most malignant cells. 1 The amino acid sustains highly proliferative cells by contributing to the biosynthesis of amino acids and nucleotides. 2, 3 In addition, glutamine protects cells from oxidative stress by maintaining healthy glutathione levels. 4 To ensure sufficient energy production, some cancer cells also rely on glutamine to synthesize alpha-ketoglutarate to replenish TCA cycle intermediates. 5 Therefore, inhibition of glutaminolysis alone is sufficient to inhibit tumor growth in some cancers. 6 Even though glutamine directly supports tumorigenesis, developing tumors are often subject to severe glutamine restriction owing to increased uptake and poor vascularization at tumor sites. 7, 8 For example, glutamine falls to almost undetectable levels relative to normal tissues in vivo in hepatomas and sarcomas. 7 Consistently, a recent study using metabolomics analysis comparing pairedpancreatic tumor patient samples with benign adjacent tissue specimens revealed that glutamine is one of the most strongly depleted metabolites in tumors. 8 Thus, tumors need to develop multiple strategies to survive and grow in low-glutamine conditions.
Tumor suppressor p53 has been commonly described as a transcription factor that contributes to cell death and cell cycle arrest in response to various stresses. 9 Interestingly, recent reports have established that p53 also contributes to cell survival upon metabolic stress. 10 For example, p53 induces CDKN1A expression to trigger reversible cell cycle arrest upon serine depletion, which allows cancer cells to pause and manage oxidative stress thus leading to enhanced survival, whereas p53-deficient cells lacking the adaptive response display drastic cell death. 11 In addition, it was demonstrated that activation of p53 in response to lowglucose levels promotes cell adaptation through a cell cycle arrest checkpoint. 12 Similarly, we have reported that p53 is activated upon glutamine deprivation and is required for cell survival under low-glutamine conditions both in vitro and in vivo. 13 Therefore, unlike numerous DNA-damage-induced p53 signaling cascades that result in apoptosis, it appears that p53 is important for cell survival under broad nutrient restrictions. Besides promoting cell survival upon metabolic stress through induction of cell cycle arrest, p53 also activates other metabolic regulators in response to nutritional stress. For example, under glucose starvation, p53 promotes expression of Sco2 or Lpin1 to decrease the rate of glycolysis by upregulating mitochondrial oxidative phosphorylation or promoting fatty acid oxidation. 14, 15 Moreover, by driving the expression of the metabolic enzyme Gls2, and the metabolic reprogramming protein Tigar, p53 contributes to cell survival by enhancing antioxidant capacity in nutrient-depleted cells. [16] [17] [18] Thus, depending on cellular context, p53 may promote multiple survival mechanisms in response to metabolic stress.
The p53 protein is mutated in over 50% of all human cancers and is often associated with a poor prognosis. [19] [20] [21] The majority of these cancers carry a missense mutation in the DNA-binding domain of the p53 protein, with arginine residue 248 or 273 among the most frequently mutated. These are commonly referred to as 'hot spot' mutations and often result in a more stable full-length protein with gain-of-function activity. 22 Intriguingly, several phenotypes of tumor-associated mutant p53 (mutp53) suggest that tumors acquire the ability to promote cancer aggression and invasion. 23 Despite evidence supporting the role of wild-type p53 (wtp53) in cell survival upon metabolic stress, it remains unclear whether mutp53 proteins could confer a survival advantage in response to metabolic stress.
In this study, we investigate the cellular response of mutp53 proteins upon glutamine withdrawal. We found that mutp53 promotes cell survival upon glutamine deprivation and glutaminase inhibitor treatment both in vitro and in vivo. Our study demonstrates that mutp53 amplifies the pro-survival effects of wtp53 protein to protect cancer cells from low-glutamine conditions.
RESULTS
Cancer cells with mutp53 are more resistant to glutamine deprivation than cells with wtp53 To determine whether p53 status can impact the survival of cancer cells upon glutamine starvation, we analyzed a panel of lymphoma cell lines with known p53 status by withdrawing glutamine over time. Strikingly, we found cells expressing mutp53 (CA46, DB and SupT1) were significantly more resistant to glutamine deprivation than cells expressing wtp53 (EB3, OCI-LY3 and DOHH2; Figure 1a) . Consistent with this, we found increased apoptosis, as measured by cleaved-PARP and cleaved-caspase 3 in EB3 cells expressing wtp53 compared with CA46 cells expressing mutp53 upon glutamine starvation (Figure 1b) . Moreover, using annexin-V and propidium iodide (PI) staining, we confirmed substantial induction of early and late apoptosis in wtp53 cells, but not in mutp53 cells (Figures 1c and d) . To further confirm resistance to cell death in glutamine-restricted conditions, we measured cell viability of EB3 and CA46 cells after treatment with the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine (L-DON). Although L-DON, a glutamine analog, has been shown to directly bind and inhibit human glutaminase, the compound also affects the activity of other glutamine-utilizing enzymes. 24 Therefore, we also treated cells with other identified glutaminase inhibitors such as bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) 25 and compound 968. 6 Consistently, we found that L-DON, BPTES and compound 968 treatments induced cell death in a dose-dependent manner in wtp53-expressing EB3 cells, whereas having no effect on cell viability of CA46 cells harboring mutp53 (Figure 1e) . Together, these results demonstrated that mutp53 status correlates with better survival in glutaminedeprived conditions and upon glutaminase inhibitor treatment.
Loss of mutp53 sensitizes cancer cells to glutamine deprivation and glutaminase inhibitor treatment To determine whether loss of mutp53 could sensitize cancer cells to glutamine starvation, we used small hairpin RNA (shRNA) to knock down mutp53 in CA46 cells. We generated stable cell lines with p53 knocked down (Figures 2a and b) , and found that mutp53 deficiency significantly sensitized CA46 cells to glutamine deprivation compared with control ( Figure 2c ). On the basis of the annexin-V/PI staining, glutamine deprivation resulted in more marked apoptotic cell death in mutp53-knockdown cells compared with vector control cells (Figures 2d and e) . In addition, we found that knockdown of mutp53 sensitized cells to different glutaminase inhibitor treatment, such as L-DON, BPTES and compound 968 (Figure 2f ). These results demonstrated that mutp53 is required for cell survival under glutamine deprivation and glutaminase inhibitor treatment.
Expression of mutp53 promotes cell survival upon glutamine deprivation and glutaminase inhibitor treatment To directly test whether mutp53 promotes cell survival upon glutamine deprivation, we stably transduced p53-deleted colorectal carcinoma HCT116 cells with retroviral vectors expressing tumor-associated p53 hotspot mutants R248Q or R273H (Figure 3a) . Expression of either p53 mutant in HCT116 p53
− / − cells largely protected cells from glutamine deprivation compared with control ( Figure 3b ). In agreement, cells expressing mutp53 displayed less apoptosis as measured by cleaved-PARP and cleaved-caspase 3 upon glutamine deprivation compared with vector control cells ( Figure 3c ). In addition, we compared survival upon glutamine deprivation in HCT116 cells with p53 deletion (Vec), and cells expressing either endogenous wtp53 or exogenous mutp53 (R248Q, R273H). Consistent with previous reports, cells with wtp53 are more resistant to glutamine deprivation than p53 null cells (Figure 3d) . 13 More interestingly, we found that cells expressing mutp53 displayed better survival than cells expressing wtp53, indicating mutp53 may acquire additional function to promote cell survival in response to glutamine deprivation. Consistent with the cellular response to glutamine deprivation, cells expressing mutp53 are significantly more resistant to both L-DON treatment and compound 968 treatment than vector control cells (Figure 3e ). Interestingly, expression of mutp53 had no significant protection upon treatment of different genotoxic agents including camptothecin, doxorubicin and docetaxel (Figure 3f ), suggesting that mutp53 might specifically promote cell survival upon metabolic stress. Altogether, these results strongly support a robust survival role of mutp53 proteins in protecting cancer cells from glutamine starvation.
Mutp53 induces expression of p53-target genes upon glutamine deprivation It has been reported that cell survival promoted by wtp53 upon metabolic stress is often mediated by the induction of cell cycle arrest and metabolic reprogramming genes including CDKN1A, GADD45A, GLS2 and TIGAR.
11,16,17 Therefore, we asked whether mutp53 contributes to the induction of these genes upon glutamine deprivation. Consistent with previous investigations, we found p53 was phosphorylated on serine 15, a critical site for p53 activation, upon glutamine deprivation in EB3 cells with wtp53 (Figure 4a) . 13 Moreover, mutp53 in CA46 cells was also phosphorylated upon glutamine deprivation (Figure 4a ). Consistent with the phosphorylation, we found that p53-targeted prosurvival genes were significantly induced in CA46 cells upon glutamine deprivation (Figure 4b) . Interestingly, the induction of these genes was more robust in CA46 cells harboring mutp53 than EB3 cells with wtp53 ( Figure 4b ). Importantly, we found that knockdown of p53 in both wtp53 and mutp53 cells markedly inhibited the induction of the survival genes upon glutamine deprivation, demonstrating that, similar to wtp53, mutp53 contributes to the upregulation of the p53-target genes (Figures 4c and d) . To further confirm that mutp53 promotes the induction of these p53-target genes, we evaluated the effect of ectopically expressed mutp53 on gene expression upon glutamine deprivation. Consistent with previous investigations, expression of CDKN1A, GLS2, GADD45A and TIGAR are significantly higher in wtp53-expressing cells compared with p53-deleted cells (Figures 4e and f) . Strikingly, we found that expression of R248Q or R273H mutp53 in HCT116 cells robustly induced CDKN1A, GLS2, GADD45A and TIGAR expression upon glutamine starvation compared with p53-deleted cells or wtp53-expressing cells (Figure 4f ). Conversely, no significant changes were found in the expression of proapoptotic gene, BAX (Figure 4f ). Together, these results suggest that mutp53 not only retains, but also exaggerates the transactivation activity of the wtp53 protein toward prosurvival genes to promote cell survival in response to glutamine deprivation.
Mutp53 directly binds to the promoter of p53-target genes upon glutamine deprivation To investigate whether mutp53 can regulate the expression of the pro-survival genes via direct binding to DNA, we performed chromatin immunoprecipitation assays (ChIP) to assess p53 occupancy on promoter regions of target genes upon glutamine deprivation. We found that binding of endogenous mutp53 R248Q to the promoters of CDKN1A, GLS2 and BAX in CA46 cells Gln-free medium overnight. mRNA expression of p53-target genes relative to 18S was determined using qRT-PCR and normalized to the complete medium. (c) Cells were transduced with lentiviral particles followed by puromycin selection to generate stable knockdown of wtp53 in EB3 cells and mutp53 in CA46. p53 protein levels were determined by western blot. (d) EB3 and CA46 cells infected with virus containing control vector or shRNA against p53 were cultured in Gln-free medium overnight. mRNA expression of p53-target genes relative to actin was determined using qRT-PCR and normalized to the complete control medium. (e) HCT116 p53 − / − cells expressing R248Q, R273H or empty vector were cultured in Gln-free medium for 3 days. p53 activation and total p53 expression were determined by the western blot analysis using anti-phospho-p53 (Ser-15) and anti-p53 antibody. (f) HCT116 p53 +/+ cells and HCT116 p53 − / − cells expressing R248Q, R273H or empty vector were cultured in complete or Gln-free medium overnight. mRNA expression of p53-target genes relative to actin was determined using qRT-PCR and normalized to the complete medium. Data represent mean ± s.d. of duplicates from two independent experiments (*Po 0.05, **P o0.01, ***P ⩽ 0.001, Student's t-test).
was very weak in complete medium (Figure 5a) . However, the binding of mutp53 to the promoter of CDKN1A and GLS2 markedly increased upon glutamine deprivation (Figure 5a) , consistent with the increased gene expression as shown in Figure 4f . Interestingly, no noticeable binding of mutp53 to the promoter of the proapoptotic gene BAX was found, even upon glutamine deprivation, supporting that mutp53 gains transactivation activity toward 'survival' genes, but not 'death' genes in response to metabolic stress, consistent with BAX expression (Figure 4f ) and previously published reports. [26] [27] [28] To further confirm this, HCT116 p53 − / − cells expressing either mutp53 or vector control were subjected to glutamine deprivation overnight before the chromatin complexes were harvested for ChIP analysis (Figure 5b) . Consistently, we found that binding of mutp53 to promoters of CDKN1A, GADD45A, TIGAR and GLS2 increased strikingly upon glutamine withdrawal. No binding of mutp53 to the promoter region of proapoptotic gene BAX was found in cells cultured in either complete or glutamine-free medium, whereas binding of wtp53 with BAX promoter was detected and increased upon glutamine deprivation (Figure 5b) . Together, these results suggest that mutp53 can directly bind to p53-response elements in the promoter region of the 'survival' genes in response to glutamine withdrawal, with possible selectivity toward pro-survival but not pro-death gene activation.
Mutp53 promotes cell survival upon glutamine deprivation through p21 induction It has been reported that wtp53-dependent p21 activation and cell cycle arrest promoted cell survival upon serine starvation.
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To determine if mutp53 promotes cell survival upon glutamine deprivation via a similar mechanism, we first examined the cell cycle profile of HCT116 p53
− / − cells with ectopic mutp53 or control vector in response to glutamine deprivation. We found that glutamine deprivation led to significant cell cycle arrest at G1/S phase in cells expressing mutp53 (Figures 6a and b) . On the other hand, glutamine +/+ cells or HCT116 p53 − / − cells expressing R248Q, R273H or vector control were cultured in complete or Gln-free medium for 16 h. ChIP analysis was performed to determine p53 binding to the promoter of p53-target genes. DNA-protein complexes were pulled down using total p53 antibody (DO-1) or isotype-matched IgG. All p53 binding sites were assessed by PCR. PCR products were separated using agarose electrophoresis.
Mutp53 promotes survival upon glutamine deprivation TQ Tran et al deprivation did not result in G1/S arrest of p53-deleted cells, indicating that cell cycle arrest may contribute to cell survival upon glutamine deprivation in mutp53 cells. The cell cycle arrest upon glutamine deprivation seen in mutp53-expressing cells is likely to be mediated by p21 induction, owing to the role of p21 in inhibiting G1/S cell cycle progression. 29, 30 To further test this, we examined p21 levels in HCT116 p53
− / − cells expressing mutp53, or an empty vector cultured in either complete or glutamine-free medium using western blot analysis. Consistent with Figures 4f and 5b, p21 protein was significantly induced upon glutamine deprivation in cells expressing mutp53 R248Q, but not in vector control cells (Figure 6c ). To further determine if the induction of p21 in mutp53 cells contributes to cell survival in low-glutamine conditions, we used small interfering RNA (siRNA) to transiently knock down p21 in HCT116 p53
− / − cells expressing either mutp53 or vector control. Importantly, we found that p21 depletion increased cell sensitivity in response to glutamine deprivation in cells expressing mutp53, suggesting that the protective effects of mutp53 are mediated through p21 expression (Figure 6d ). In addition, this increased sensitivity correlated with an increase in apoptosis, as indicated by western blot analysis of cleaved-PARP (Figure 6e) . Conversely, p21 depletion had no effect on cell viability upon glutamine deprivation in p53-deleted cells expressing vector control (Figures 6d and e) . Taken together, these results demonstrate that mutp53 induces p21-dependent cell cycle arrest, which promotes cell survival in low-glutamine conditions. Tumors expressing mutp53 are more resistant to glutaminase inhibitor treatment in vivo To further investigate whether mutp53 can protect cancer cells from glutamine starvation in vivo, we established xenograft tumors using HCT116 p53 − / − cells expressing either an empty vector or mutp53 R248Q. Once tumors were established, mice were treated with the glutaminase inhibitor L-DON and tumor volume was measured over time (Figures 7a and b) . As expected, inhibition of glutamine metabolism by L-DON markedly suppressed growth of the p53 null tumors. In contrast, L-DON − / − cells expressing mutp53 (R248Q) or empty vector were cultured in complete or Gln-free medium for 24 h. PI staining followed by flow cytometry was performed to assess cell cycle profile. Representative graphs of three independent experiments are shown. Data represent the mean ± s.
d. (c) HCT116 p53
− / − cells expressing mutp53 R248Q or empty vector were cultured in complete or Gln-free medium for 24 h. Western blots were performed using antibodies as indicated. (d) p21 was transiently knocked down in HCT116 p53
− / − cells expressing mutp53 R248Q or empty vector using siRNA (20 nM). Fortyeight hours after the siRNA transfection, cells were cultured in complete or Gln-free medium for 4 days. Cell viability was determined by trypan blue exclusion. Data represent the mean ± s.d. of four independent experiments, (***P ⩽ 0.001, Student's t-test). (e) Western blot was performed using antibodies as indicated.
treatment had no significant effect on growth of tumors with mutp53 R248Q (Figures 7a and b) . Consistent with our previous results, L-DON treatment induced apoptosis as indicated by cleaved-PARP in p53 null tumors, but not in tumors expressing mutp53 (Figure 7c) . Together, these results show that mutp53 may have a role in tumor resistance to glutamine deprivation in vivo.
DISCUSSION
More than half of human cancers carry mutations in the TP53 gene. These tumor-associated mutp53 proteins have been previously shown to drive aggressive cancer growth, metastasis and chemotherapeutic drug resistance. 31 However, whether mutp53 proteins can protect cancer cells from metabolic stress that commonly occurs in the tumor microenvironment is not well established. Our results demonstrate that tumor-associated mutp53 proteins promote cancer cell survival in response to glutamine starvation both in vitro and in vivo. Altogether, the data reveal a previously unidentified mechanism by which mutp53 promotes tumorigenesis through resistance to metabolic stresses.
In this paper, we found that mutp53 can directly bind to the promoters of p53-target genes that regulate either cell cycle or metabolism, and induce their expression upon glutamine deprivation (Figures 4 and 5) . Although mutp53 proteins acquire noncanonical transactivation activity to promote cancer growth and invasion, recent studies demonstrate that mutp53 can bind to the response elements of wtp53. 32 Studies in both yeast and mammalian systems reveal that mutp53 proteins have differential transactivation activity toward canonical p53-target genes including loss of function, reduced transactivation activity and super-transactivation activity. 33 Moreover, mutp53 proteins can differentially regulate canonical p53-target genes to modulate cellular response to stress. For example, mutp53 may confer a survival advantage through its ability to transactivate the cell cycle arrest gene CDKN1A, but not the proapoptotic gene BAX.
26-28
These evidences support our findings that mutp53 can transactivate the expression of p53-target genes to support cell survival and adaptation during metabolic stress. However, it still remains unclear how these mutp53 proteins are recruited to promoters of the target genes in response to metabolic stress. On the basis of our ChIP analysis, the binding of mutp53 to the target promoters remained minimal in normal conditions, but markedly increased in response to glutamine withdrawal. These results suggest that other factors or pathways induced by glutamine deprivation might be required for the transactivation activity of mutp53. For example, upon glucose deprivation, PGC-1 protein can bind and preferentially promote p53 transactivation activity toward genes associated with cell cycle arrest and metabolic regulation. 34 Therefore, it will be of interest to determine the molecular mechanisms that modulate the transactivation of mutp53 toward pro-survival genes in response to metabolic stress. Our data also demonstrate that induction of CDKN1A (p21) is required for mutp53-mediated cell survival under low-glutamine conditions. It has been well established that activation of wtp53 upon metabolic stress can contribute to survival through induction of cell cycle arrest genes. For example, AMPKdependent p53 activation upon glucose starvation promotes cell cycle arrest at the G1/S phase transition, leading to improved cellular survival. 12 In addition, p53 in serine-depleted cells can promote p21-dependent cell cycle arrest and antioxidant biosynthesis, which together support adaptation and cellular survival. 11 Here, we found that mutp53 proteins not only retain, but also amplify the survival effect of wtp53 to protect cancer cells from glutamine deprivation via induction of p21. Specifically, mutp53 hyperinduces p21 expression to promote G1/S cell cycle arrest to protect cells from glutamine deprivation. Moreover, we observed that p21 knockdown is sufficient to restore cell sensitivity of mutp53 cells to glutamine deprivation. Cell cycle arrest upon metabolic stress can serve as a critical initial response that stops the energy-demanding process of cell proliferation to allow other cellular repair and adaptive processes to occur. Therefore, elimination of cell cycle arrest in glutamine-deprived cells leads to unchecked proliferation and failure to adapt to metabolic stress, causing decreased cell viability. Besides p21, other p53-target genes involved in cell cycle arrest or metabolism are also highly induced in cells expressing mutp53 upon glutamine deprivation. Although our data support that p21 is critical for mutp53-mediated survival, we cannot exclude that other mutp53-regulated pathways also contribute to cell survival under glutamine deprivation. For example, it was recently reported that mutp53 proteins can directly bind to the metabolic protein sensor, AMPK, and inhibit its function to promote cancer cell growth. 35 In addition, tumor-associated mutp53 has been shown to stimulate the Warburg effect. 36 The resistance to glutamine restriction in mutp53-expressing cells can impact tumor physiology and therapeutic response. First, glutamine levels at tumor sites can drop to nearly undetectable levels, partially because tumors heavily use exogenous glutamine to sustain their growth and survival. As glutamine is depleted in poorly vascularized tumor microenvironment, cancer cells expressing mutp53 protein are able to adapt and survive the metabolic stress, whereas p53-deficient cells and wtp53-expressing cells will experience impaired proliferation and increased cell death. Therefore, the glutamine-depleted environment within tumors is more favorable for the development of cancer cells expressing mutp53 proteins. Second, targeting glutamine metabolism underscores a therapeutic benefit against cancers. [37] [38] [39] Recently, there is an increasing effort to inhibit anabolic glutamine metabolism using small-molecule inhibitors targeting glutaminase. For example, BPTES has been shown to inhibit growth of lymphoma xenografts with minimal toxicity, and a more potent glutaminase inhibitor CB-839 is currently in clinical trial for triple-negative breast cancer. 40, 41 However, we found that mutp53-expressing cells are strongly resistant to glutamine depletion and glutaminase inhibitor treatment compared with p53-deficient cells. These findings suggest a potential benefit in using glutaminase inhibitors to treat patients with p53-deficient tumors, but not those with tumors harboring mutp53.
MATERIALS AND METHODS

Cell culture and reagents
HCT116 p53
+/+ and HCT116 p53 − / − cells were cultured in Dulbecco's modified Eagle medium (DMEM, Corning, New York, NY, USA) supplemented with 10% fetal bovine serum (Gemini Bio-Products, Sacramento, CA, USA), 100 units/ml of penicillin and 100 μg/ml of streptomycin (Gemini Bio-Products). These cells have been generated previously.
42 EB3, SUPT1, DB (purchased from ATCC (Manassas, VA, USA)) and DOHH2 (purchased from DSMZ, Braunschweig, Germany) lymphoma cell lines were cultured in RPMI 1640 medium (Corning) with 10% fetal bovine serum, 100 units/ml of penicillin and 100 μg/ml of streptomycin (Gemini Bio-Products). CA46 (purchased from ATCC) and OCI-LY3 (purchased from DSMZ) cells were cultured in RPMI medium with 20% fetal bovine serum. All cells were cultured at 37°C with 5% CO 2 . All cells were routinely tested for mycoplasma contamination using MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland). L-DON, BPTES and camptothecin were purchased from Sigma (St Louis, MO, USA). Docetaxel was purchased from Selleckchem (Houston, TX, USA) and compound 968 was purchased from MilliporeSigma (Darmstadt, Germany).
Glutamine starvation
For glutamine-deprivation experiments, cells were washed once with 1 × phosphate-buffered saline (PBS), and cultured in glutamine-free medium or complete medium. To make glutamine-free medium, DMEM and RPMI without glutamine (Corning) were supplemented with 10% dialyzed fetal bovine serum (Gemini Bio-Products). To make the complete medium, 2 mM L-glutamine (Corning) was added back to the glutaminefree medium.
Flow cytometry
To assess cell viability, cells were washed once with PBS and stained with 1 μg/ml PI (Thermo Fisher Scientific, Waltham, MA, USA) for 10 min at room temperature. To assess apoptotic cell death, cells were washed once with PBS, and stained with PI and annexin-V (eBioscience, San Diego, CA, USA), and processed according to the manufacturer's protocol. Flow analysis was carried out using the 9-color CyAn ADP from Beckman Coulter (Miami, FL, USA). To assess cell viability by trypan blue exclusion, cells were washed once with PBS and stained with trypan blue solution (Sigma). Cell viability was determined using TC20 automated cell counter (Bio-Rad, Hercules, CA, USA).
Cell cycle staining
To assess cell cycle profiles, cells were washed once with PBS and fixed with ice-cold 70% ethanol overnight. Fixed cells were washed twice with PBS and then treated with RNase A (Sigma) for 10 min at 37°C. The cells were then stained with PI (Thermo Fisher Scientific) and analyzed by flow cytometry on the CyAn ADP.
Real-time reverse transcription PCR RNA extractions were performed using Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's guidelines. RNA of 1 μg was used for each complementary DNA synthesis reaction (Quanta Biosciences, Beverly, MA, USA). Quantitative real-time reverse transcription PCR reactions were performed with SYBR Green PCR reagents (Quanta Biosciences) using an iQ5 thermal cycler (Bio-Rad). The cycle threshold values of the target genes were normalized to cycle threshold values of actin or 18S. Forward and reverse primers were generated to check gene expression. 18S-F: 5′-CGCTTCCTTACCTGGTTGAT-3′ R: 5′-GAGCGACCAA AGGAACC ATA-3′; ACTIN-F: 5′-CACCAACTGGGAGGACAT-3′ R: 5′GCACAGCCT GGA TAGCAAC-3′; CDKN1A-F: 5′-AGGTGGACCTGGAGACTCTCAG-3′ R: 5′TCC TCTTGGAGAAGATCA GCCG-3′; GADD45A-F: 5′-CTGGAGGAAGTGC TCAG CAAAG-3′ R: 5′-AGAGCCACA TCTCTGTCGTCGT-3′; GLS2-F: 5′-CAGAAGG CACAGACATGGTTGG-3′ R: 5′-GGCA GAAACCACCATTAGCCAG-3′; TIGAR-F: 5′-TTCGGGAAAGGAAATACGGGG-3′ R: 5′-CCACGCATTTTCACCTGGTC-3′; SESN2-F: 5′-GCGCTTTCATTCCAGTGGAAGAG-3′ R: 5′-CAGAAGCTGCTAAG GTAGTCCG-3′; BAX-F: 5′-CCCGAGAGGTCTTTTTCCGAG-3′ R: 5′-CCAG CCCATGATGGTTCTGAT -3′.
Western blotting
Immunoblotting was carried out as described previously. 43 Briefly, cells were washed three times with PBS and lysed in ice-cold RIPA lysis buffer shRNA knockdown p53 shRNA constructs (TRCN0000003753) were purchased from GE Dharmacon (Lafayette, CO, USA). shRNA lentiviral particles were generated in 293T cells as described previously. 43 Briefly, 293T cells were co-transfected with pLKO.1 empty vector or p53 shRNA vector, pMDL, pCMV-VSV-G and pRSV-Rev at a ratio of 4:2:1:1. After the transfection, lentiviral particles were collected at day 2 and day 3. Lymphoma cells were spin-infected twice with the lentiviral particles for 50 min at 2000 r.p.m. at 30°C. Cells were selected with 0.25 μg/ml puromycin. siRNA knockdown On-target plus human CDKN1A siRNA from Dharmacon (SMARTpool L-003471) was used to transiently knock down p21 protein in HCT116 cells. Cells were transfected with CDKN1A siRNA or control siRNA (Dharmacon) using RNAi max lipofectamine reagent (Invitrogen). Glutamine-deprivation experiments were performed 48 h post siRNA transfection.
Generation of stable cell lines expressing mutp53 proteins pLPCX retroviral vectors expressing mutp53 R248Q or R273H were generous gifts from Dr Zhaohui Feng's Laboratory (Rutgers University, New Jersey). A total of 293T cells were transfected with the mutp53-expressing vectors and the pLPCX empty vectors as previously described to generate retroviral particles. 43 HCT116 p53 − / − cells were cultured with the virus containing medium with 10 μg/ml polybrene overnight, followed by puromycin selection (1 μg/ml).
Chromatin immunoprecipitation assay
The ChIP assay was performed using a ChIP assay kit (MilliporeSigma) according to the manufacturer's guideline. In brief, cells were cultured in complete medium or glutamine-free medium overnight. Cells were crosslinked with 1% formaldehyde for 10 min at room temperature. Cells were washed three times with PBS and lysed in ice-cold lysis buffer with protease inhibitors on ice for 5 min. Samples were sonicated to yield 200-1000 bp DNA fragments. After centrifugation, cell supernatant was diluted in immunoprecipitation buffer with protease inhibitors and precleared with salmon sperm DNA/protein A agarose for 1 h at 4°C with rotation. 1 μg of p53 (DO-1, Santa Cruz Biotechnology) or IgG antibody was used for each overnight immunoprecipitation with rotation at 4°C. Binding sites of p53 were amplified by 30-35 cycles of PCR using Hotstart Taq DNA polymerase (Bioneer). The PCR products were detected using agarose gel electrophoresis. PCR primers for the ChIP assays: CDKN1A-F: 5′-GCTG TGGCTCTGATTGGCTTT-3′ R: 5′-ACAGGCAGCCCAAGGACAAA-3′; GADD45A -F: 5′-AGCGGAAGAGATCCCTGTGA-3′ R: 5′-CGGGAGGCAGGCAGATG-3′; GLS2-F: 5′-GGCCTCCCAAGTCACCAGTTCA-3′ R: 5′TGTTTTTGCTTGTTTTC GCCTTCT-3′; TIGAR-F: 5′-GCTTCAGACGTATATATAGA-3′ R: 5′GGGGCTA TTCT TGGTAGTAA-3′; BAX-F: 5′-GGGTTATCTCTTGGGCTCACAA-3′ R: 5′-GAGCTCTCCCCAGCGCA-3′; Negative primer-F: 5′-TAAATGGGACAGGTA GGACC-3′ R: 5′-TCCACCGCTTCTTGTCCTGC-3′.
Mouse xenografts
All animal procedures were approved by the Institutional Animal Care and Use Committee at City of Hope Cancer Center in compliance with ethical regulations. Animal were randomized before treatments. Sample size was generally chosen based on preliminary data indicating the variance within each group and the differences between groups. 7-week-old athymic nude male mice (Taconic Laboratories, Hudson, NY, USA) were injected subcutaneously with 1 × 10 6 cells. HCT116 p53
− / − cells expressing vector control were injected in the left flank and HCT116 p53 − / − cells expressing mutp53 R248Q were injected in the right flank. When the tumor size reached an average of 60 mm 3 , mice were treated with 15 mg/kg of L-DON or PBS 3 times per week. The tumor size was measured every other day as described previously. 44 Eleven days after the drug treatment, the mice were killed and the tumors were harvested for the western blot analysis.
Statistical analysis
Results are shown as averages; error bars represent either the s.e.m. or s.d. as indicated. The unpaired Student's t-test was used to determine the statistical significance of differences between means (*P o 0.05, **P o 0.01, ***P ⩽ 0.001). All western blot experiments were repeated at least three times with a representative gel being shown. For all other experiments, each was repeated independently at least two times with similar results.
